Sparrow Pharma Phase 2a data back clofutriben in Type 2 diabetes
Sparrow Pharmaceuticals has presented Phase 2a clinical data showing that clofutriben, its lead 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, produced statistically significant cardiometabolic improvements in adults with Type 2 diabetes. The results were disclosed at the 2026 American Diabetes Association Annual Scientific Session in Boston.
In the intent-to-treat population of 75 participants, six weeks of once-daily 10 mg clofutriben produced placebo-adjusted reductions in HbA1c of 0.36 percentage points, glucose of 1.64 mmol/L, and total cholesterol of 0.76 mmol/L. The trial — originally designed to assess neuropathic pain — was a randomised, double-blind, placebo- and active-controlled study registered under NCT02372578.
Elevated-cortisol subset shows larger signal
A pre-specified subset of 25 patients who had inadequately controlled HbA1c despite two or more antidiabetic medications — a proxy population for elevated cortisol risk — showed numerically greater improvements across all measured cardiometabolic parameters. HbA1c fell by 0.51 percentage points, glucose by 3.43 mmol/L, total cholesterol by 1.17 mmol/L, and triglycerides by 0.86 mmol/L. Weight declined by 1.3 kg, and modest reductions in systolic and diastolic blood pressure were recorded.
The safety profile was broadly clean: the majority of adverse events were mild or moderate, with no clinically significant signals in laboratory, vital-sign, or electrocardiogram data. One patient discontinued after thrombocytopenia was reported as a serious adverse event; the individual had an undisclosed history of idiopathic thrombocytopenic purpura, which complicates causal attribution.
Robert Jacks, President and Chief Executive of Sparrow Pharmaceuticals, said the data "reinforce our conviction that clofutriben could play an important role in improving not only glycemic control but also broad cardiometabolic dysfunction," adding that the cortisol mechanism addresses "an often-overlooked driver of treatment resistance and disease progression."
Market context and competitive landscape
The HSD-1 inhibitor class has had a complicated history: earlier candidates from larger pharmaceutical groups, including work by AstraZeneca and Merck, did not progress to approval in metabolic indications, partly owing to modest glycaemic effect sizes. Sparrow's strategy of enriching for patients with elevated cortisol is a deliberate attempt to identify the subset most likely to respond, which may strengthen the regulatory and commercial case if the signal holds in Phase 2b.
Sparrow's ongoing CAPTAIN-T2D trial — a dose-ranging, double-blind Phase 2b study — is evaluating clofutriben specifically in patients with inadequately controlled Type 2 diabetes and confirmed elevated cortisol. The primary endpoint is HbA1c change at 24 weeks, a significantly longer observation window than the six weeks reported today. Exploratory endpoints include body weight, blood pressure, cholesterol, and bone metabolism biomarkers.
The broader cardiometabolic market remains highly competitive, with GLP-1 receptor agonists having set a high bar for weight and glycaemic outcomes. However, GLP-1 agents carry gastrointestinal tolerability burdens and access constraints that leave a meaningful patient population seeking alternatives. An oral, once-daily agent with a cortisol-targeting mechanism could find a niche among patients with difficult-to-control disease, provided the Phase 2b data confirm and extend today's readout. The CAPTAIN-T2D results will be closely watched by investors and potential partners assessing Sparrow's partnering or financing optionality.